Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent ...

Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent ...

Transactions position the company to advance Prana’s pipeline of next-generation, half-life-extended multispecific antibodies enabled by its proprietary INSPIRE platformPRA-216 is a novel IL-4Rα/TSLP bispecific antibody currently in Phase 2 development for asthma, COPD, and atopic dermatitis, with a Phase 2…

Bolt (NASDAQ: BOLT) announces Prana acquisition and $120 million financing

What happened Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) said it is acquiring Prana Therapies and raising $120 million in upfront financing. The deal is structured as a sign-and-close reverse merger, with Prana equity swapped for Bolt common stock and Series D non-voting convertible preferred stock. Bolt said the private placement could add up to another $60 […]